Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.52 -6.8%	$28.86	$22.74 ▼ $53.96	$1.12B	0.79	456,452 shs	840,588 shs
INDV Indivior	$8.94 -7.7%	$9.65	$7.33 ▼ $20.67	$1.34B	0.93	925,419 shs	444,365 shs
RGNX REGENXBIO	$5.41 -8.5%	$7.05	$5.04 ▼ $19.38	$270.97M	1.26	789,333 shs	1.55 million shs
WVE Wave Life Sciences	$5.48 -10.7%	$9.56	$4.25 ▼ $16.74	$841.10M	-0.93	1.18 million shs	1.82 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-6.78%	-13.66%	-13.94%	-35.31%	-41.27%
INDV Indivior	-7.74%	-4.69%	-8.50%	-24.56%	-56.11%
RGNX REGENXBIO	-8.46%	-18.89%	-11.46%	-27.96%	-71.30%
WVE Wave Life Sciences	-10.75%	-17.47%	-47.31%	-52.51%	-9.27%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.1735 of 5 stars	3.0	3.0	3.7	2.2	4.2	1.3
INDV Indivior	3.2873 of 5 stars	3.6	3.0	0.0	3.2	1.7	1.9
RGNX REGENXBIO	4.6073 of 5 stars	4.4	2.0	4.6	3.2	2.5	1.3
WVE Wave Life Sciences	4.4283 of 5 stars	3.5	3.0	4.8	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.00	Hold	$43.50	84.95% Upside
INDV Indivior	3.25	Buy	$15.00	67.79% Upside
RGNX REGENXBIO	2.86	Moderate Buy	$32.78	505.87% Upside
WVE Wave Life Sciences	3.00	Buy	$22.18	304.78% Upside

Current Analyst Ratings Breakdown

Latest RGNX, AMPH, INDV, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	WVE Wave Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00
3/14/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
3/5/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.53	$3.28 per share	7.17	$13.35 per share	1.76
INDV Indivior	$1.19B	1.04	$1.81 per share	4.94	N/A	∞
RGNX REGENXBIO	$83.33M	3.25	N/A	N/A	$7.09 per share	0.76
WVE Wave Life Sciences	$108.30M	7.77	N/A	N/A	$0.40 per share	13.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	7.84	7.15	2.19	21.80%	26.44%	11.89%	5/6/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	5.23	N/A	-3.96%	-241.73%	15.09%	4/24/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$4.61	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	5/6/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.79	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	5/8/2025 (Estimated)

Latest RGNX, AMPH, INDV, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.26	N/A	N/A	N/A	$11.65 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	N/A	N/A	N/A	$240.13 million	N/A
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million
3/4/2025	Q4 2024	WVE Wave Life Sciences	-$0.17	$0.17	+$0.34	$0.17	$25.60 million	$83.75 million
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
INDV Indivior	N/A	0.83	0.65
RGNX REGENXBIO	N/A	3.05	3.05
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
INDV Indivior	60.33%
RGNX REGENXBIO	88.08%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
INDV Indivior	N/A
RGNX REGENXBIO	13.13%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.65 million	35.05 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
RGNX REGENXBIO	370	50.09 million	43.04 million	Optionable
WVE Wave Life Sciences	240	153.49 million	108.14 million	Optionable

RGNX, AMPH, INDV, and WVE Headlines

Recent News About These Companies

Wave Life Sciences (NASDAQ:WVE) Now Covered by Analysts at Wedbush

April 10 at 10:40 AM | marketbeat.com

Wedbush Initiates Coverage on Wave Life Sciences (NASDAQ:WVE)

April 10 at 3:13 AM | americanbankingnews.com

Wedbush starts RNA-focused standout Wave Life Sciences with an Outperform

April 8 at 10:30 PM | markets.businessinsider.com

Trexquant Investment LP Has $5.44 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 7, 2025 | marketbeat.com

Cinctive Capital Management LP Lowers Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 5, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Trading Down 2.8% - What's Next?

April 4, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Gap Down - What's Next?

April 3, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)

April 2, 2025 | markets.businessinsider.com

Wave’s Duchenne Therapy Has Promising Phase 2 Results

April 2, 2025 | managedhealthcareexecutive.com

Q1 Earnings Forecast for WVE Issued By Leerink Partnrs

April 1, 2025 | americanbankingnews.com

What is Leerink Partnrs' Estimate for WVE Q1 Earnings?

March 31, 2025 | marketbeat.com

Loomis Sayles & Co. L P Takes $20.55 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30, 2025 | marketbeat.com

Artisan Partners Limited Partnership Trims Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30, 2025 | marketbeat.com

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

March 28, 2025 | zacks.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Position Increased by Swiss National Bank

March 28, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

March 28, 2025 | marketbeat.com

WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD

March 27, 2025 | ajmc.com

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

March 27, 2025 | seekingalpha.com

Wave Life releases positive Phase II results for WVE-N531 in DMD

March 27, 2025 | thepharmaletter.com

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

March 27, 2025 | finance.yahoo.com

HC Wainwright Reaffirms Buy Rating for Wave Life Sciences (NASDAQ:WVE)

March 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, AMPH, INDV, and WVE Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.52 -1.71 (-6.78%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$23.50 -0.02 (-0.09%)

As of 04/10/2025 07:06 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Indivior NASDAQ:INDV

$8.94 -0.75 (-7.74%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$8.95 +0.01 (+0.11%)

As of 04/10/2025 04:05 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

REGENXBIO NASDAQ:RGNX

$5.41 -0.50 (-8.46%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$5.69 +0.28 (+5.25%)

As of 04/10/2025 07:03 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Wave Life Sciences NASDAQ:WVE

$5.48 -0.66 (-10.75%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$5.66 +0.18 (+3.19%)

As of 04/10/2025 06:21 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time